Who Paid My Doc
Vonvendi
Biological Hematology
NDC 0944-7551-02
General payments
$34,474,398
Research payments
$3,529,216
Through program year 2025, $34,474,398 in general payments and $3,529,216 in research payments were reported against Vonvendi (Hematology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $8,949,561 | 117 |
| 2025 | Research | $384,172 | 136 |
| 2024 | General | $9,935,463 | 150 |
| 2024 | Research | $39,703 | 21 |
| 2023 | General | $3,745,991 | 276 |
| 2023 | Research | $315,325 | 51 |
| 2022 | General | $1,937,815 | 116 |
| 2022 | Research | $197,861 | 131 |
| 2021 | General | $3,721,427 | 67 |
| 2021 | Research | $409,083 | 196 |
| 2020 | General | $3,061,371 | 47 |
| 2020 | Research | $1,453,851 | 169 |
| 2019 | General | $3,122,769 | 138 |
| 2019 | Research | $729,222 | 153 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 22 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 19 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
911 general · 857 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.